AMAG Spends $700 Million To Better Sell Makena
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase of Cord Blood Registry is expected to boost commercialization of preterm birth drug Makena, while adding a stable growth business to AMAG and offering cost synergies.